GADD45A

Across TCGA pan-cancer cohorts, GADD45A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GADD45A data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher GADD45A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GADD45A expression acts as an unfavorable survival marker.

LIHC and SARC are the cancer types where GADD45A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.014	0.543	<.001	6	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

GADD45A–LIHC (DFS)

Open the LIHC breakdown →